Recently, clinical evidence has raised BMI as an emerging prognostic factor for immunotherapy, regardless of cancer types. In this article we rewirw current data about correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer / Gelibter, Alain; Occhipinti, Mario; Pisegna, Simona; Cortellini, Alessio; Cortesi, Enrico; Marchetti, Paolo. - In: LUNG CANCER MANAGEMENT. - ISSN 1758-1966. - 9:2(2020). [10.2217/lmt-2019-0016]
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer
Gelibter, Alain
Primo
;Occhipinti, MarioSecondo
;Pisegna, Simona;Cortesi, EnricoPenultimo
;Marchetti, PaoloUltimo
2020
Abstract
Recently, clinical evidence has raised BMI as an emerging prognostic factor for immunotherapy, regardless of cancer types. In this article we rewirw current data about correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancerFile allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Gelibter_Status of correlation_2020.pdf
accesso aperto
Note: https://www.futuremedicine.com/doi/10.2217/lmt-2019-0016
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
526.14 kB
Formato
Adobe PDF
|
526.14 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
